Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Melanotan II
Also known as: MT-2, MT-II, Melanotan 2
Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that was originally developed at the University of Arizona for skin cancer prevention through tanning. It is a non-selective melanocortin receptor agonist that produces skin darkening, appetite suppression, and increased sexual arousal. It has not been approved by any regulatory agency for clinical use.
Risk Level
High RiskDifficulty
Intermediate| CAS Number | 121062-08-6 |
| Molecular Formula | C50H69N15O9 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Melanotan II activates melanocortin receptors MC1R through MC5R with varying affinity. Activation of MC1R on melanocytes stimulates eumelanin production and transfer, resulting in skin pigmentation independent of UV exposure. MC4R activation in the CNS drives the pro-sexual and appetite-suppressing effects, while MC3R activity contributes to metabolic regulation. Its broad receptor activity underlies both its diverse effects and its side effect profile.
Dosing Research
Typical loading protocols use 0.25-0.5 mg subcutaneously daily for 2-4 weeks, followed by maintenance dosing of 0.5 mg once or twice weekly. Initial doses of 0.1 mg are recommended to assess tolerance due to nausea. UV exposure enhances and accelerates the tanning effect.
Side Effects & Risks
Nausea is very common, especially at higher initial doses. Facial flushing, spontaneous erections, and appetite suppression are frequent. Changes to existing moles and nevi raise dermatological safety concerns, and regular mole monitoring is strongly recommended. Rare but serious reports of melanoma in pre-existing atypical nevi have been documented. Blood pressure changes and fatigue have also been reported.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.